Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 128 points (-0.8%) at 16,374 as of Friday, April 25, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 926 issues advancing vs. 2,054 declining with 148 unchanged. The Drugs industry currently sits down 2.3% versus the S&P 500, which is down 0.7%. On the negative front, top decliners within the industry include Cytokinetics ( CYTK), down 61.9%, Regeneron Pharmaceuticals ( REGN), down 2.6%, Actavis ( ACT), down 2.0%, Teva Pharmaceutical Industries ( TEVA), down 1.8% and Alexion Pharmaceuticals ( ALXN), down 1.2%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Intercept Pharmaceuticals ( ICPT) is one of the companies pushing the Drugs industry lower today. As of noon trading, Intercept Pharmaceuticals is down $12.44 (-4.6%) to $259.11 on light volume. Thus far, 174,363 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 603,300 shares. The stock has ranged in price between $256.13-$267.87 after having opened the day at $267.04 as compared to the previous trading day's close of $271.56. Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $5.1 billion and is part of the health care sector. Shares are up 297.7% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Intercept Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Intercept Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.